Abstract
Measures to control the spread of COVID-19 infections, such as restrictions on movement, social distancing regulations, lockdowns, and curfews, are being applied intermittently around the globe. The application of these control measures has had far-reaching effects on the health of patients with Substance Use Disorder and how services and treatment are being provided to them. In the first part of this chapter, we focus on the health and contextual effects of COVID-19 on people with Substance Use Disorder. We then present current evidence of the effects of COVID-19 on Substance Use Disorder treatment services and providers. Studies from around the globe suggest that COVID-19 has increased the vulnerability and stigma toward people who use drugs and substantially decreased their ability to access needed treatment. The second part of this chapter discusses future models for service provision and their possible benefit to Substance Use Disorder patients, emphasizing the use of telemedicine, e-prescribing, dosing flexibility, take-home medicine, and reach-out initiatives. We suggest that models of care based on remote patient management might benefit some patients, but their universal adoption with insufficient evidence could be detrimental to others needing closer clinical supervision. Using hybrid models, incorporating both person-to-person and remote treatment delivery, changing reimbursement schemes, and using new technologies may increase the benefits of remote patient care.
This is a preview of subscription content, log in via an institution to check access.
Abbreviations
- CDC:
-
Centers for Disease Control
- GPS:
-
Global positioning system
- HCV:
-
Hepatitis C Virus
- HIV:
-
Human immunodeficiency virus
- MOUD:
-
Medication for opioid use disorder
- PEP:
-
Post-exposure prophylaxis
- PPE:
-
Personal protective equipment
- PWUD:
-
People who use drugs
- SAMHSA:
-
Substance Abuse and Mental Health Services Administration
- SARS-CoV-2:
-
Severe acute respiratory syndrome coronavirus 2
- SSP:
-
Syringe service programs
- SUD:
-
Substance use disorder
References
Alexander GC, Stoller KB, Haffajee RL, Saloner B (2020) An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-1141
Andorn AC, Haight BR, Shinde S, Fudala PJ, Zhao Y, Heidbreder C, Learned SM, Fox NL, Nadipelli VR, Hassman D, Rutrick D (2020) Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol 40(3):231–239. https://doi.org/10.1097/JCP.0000000000001195
Ashford RD, Brown AM, Curtis B (2018) Systemic barriers in substance use disorder treatment: a prospective qualitative study of professionals in the field. Drug Alcohol Depend 189:62–69. https://doi.org/10.1016/j.drugalcdep.2018.04.033
Bailey P, Wenzel RP (2020) The importance of nonpharmacologic interventions for the prevention of COVID-19 transmission. In: Memish ZA (ed) Guide to infection control in the healthcare setting. International Society for Infectious Diseases. https://isid.org/guide/pathogens/the-importance-of-non-pharmacologic-interventions-for-the-prevention-of-covid-19-transmission/
Bartholomew TS, Nakamura N, Metsch LR, Tookes HE (2020) Syringe Services Program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy 83:102821. https://doi.org/10.1016/j.drugpo.2020.102821
Bergman BG, Kelly JF, Fava M, Eden Evins A (2021) Online recovery support meetings can help mitigate the public health consequences of COVID-19 for individuals with substance use disorder. Addict Behav 113:106661. https://doi.org/10.1016/j.addbeh.2020.106661
Bhaskar S, Bradley S, Chattu VK, Adisesh A, Nurtazina A, Kyrykbayeva S, Sakhamuri S, Yaya S, Sunil T, Thomas P, Mucci V, Moguilner S, Israel-Korn S, Alacapa J, Mishra A, Pandya S, Schroeder S, Atreja A, Banach M, Ray D (2020) Telemedicine across the globe-position paper from the COVID-19 pandemic health system resilience PROGRAM (REPROGRAM) international consortium (part 1). Front Public Health 8:644. https://doi.org/10.3389/fpubh.2020.556720
Cantor J, Stein BD, Saloner B (2020) Telehealth capability among substance use disorder treatment facilities in counties with high versus low COVID-19 social distancing. J Addict Med 14(6):e366. https://doi.org/10.1097/ADM.0000000000000744
Centers for Disease Control and Prevention [CDC] (May 12 2021a) Vital statistics rapid release – provisional drug overdose data. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
Centers for Disease Control and Prevention [CDC] (May 2021b) Science brief: evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html
Centers for Disease Control and Prevention [CDC] (June 4 2021c) Suspected non-fatal drug overdoses during COVID-19. CDC Injury Center. https://www.cdc.gov/drugoverdose/data/nonfatal/states/covid-19.html
Chang J, Agliata J, Guarinieri M (2020) COVID-19 – enacting a ‘New Normal’ for people who use drugs. Int J Drug Policy 83:102832. https://doi.org/10.1016/j.drugpo.2020.102832
Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, Samuels EA (2021) Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abus Treat 124:108283. https://doi.org/10.1016/j.jsat.2021.108283
Cole TO, Robinson D, Kelley-Freeman A, Gandhi D, Greenblatt AD, Weintraub E, Belcher AM (2020) Patient satisfaction with medications for opioid use disorder treatment via telemedicine: brief literature review and development of a new assessment. Front Public Health 8:557275. https://doi.org/10.3389/fpubh.2020.557275
Cone DC, Bogucki S, Burns K, D’Onofrio G, Hawk K, Joseph D, Fiellin DA (2020) Naloxone use by emergency medical services during the COVID-19 pandemic: a national survey. J Addict Med 14(6):e369–e371. https://doi.org/10.1097/ADM.0000000000000746
Conway B, Truong D, Wuerth K (2020) COVID-19 in homeless populations: unique challenges and opportunities. Futur Virol 15(6):331–334. https://doi.org/10.2217/fvl-2020-0156
Courser MW, Raffle H (2021) With crisis comes opportunity: unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic. J Subst Abus Treat 122:108220. https://doi.org/10.1016/j.jsat.2020.108220
Crowley D, Delargy I (2020) A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report. Harm Reduct J 17(1):49. https://doi.org/10.1186/s12954-020-00394-z
Currie JM, Schnell MK, Schwandt H, Zhang J (2021) Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open 4(4):e216147. https://doi.org/10.1001/jamanetworkopen.2021.6147
D’Aeth JC, Ghosal S, Grimm F, Haw D, Koca E, Lau K, Moret S, Rizmie D, Deeny SR, Perez-Guzman PN, Ferguson N, Hauck K, Smith PC, Forchini G, Wiesemann W, Miraldo M (2021) Optimal national prioritization policies for hospital care during the SARD-CoV-2 pandemic. Nat Comput Sci 1(8):521–531. https://doi.org/10.1038/s43588-021-00111-1
Davis CS, Samuels EA (2020) Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy 93:102905. https://doi.org/10.1016/j.drugpo.2020.102905
Ding K, Yang J, Chin M-K, Sullivan L, Demirhan G, Violant-Holz V, Uvinha RR, Dai J, Xu X, Popeska B, Mladenova Z, Khan W, Kuan G, Balasekaran G, Smith GA, on behalf of Global Community Health–COVID-19 Collaborative Research Team (2021) Mental Health among adults during the COVID-19 pandemic lockdown: a cross-sectional multi-country comparison. Int J Environ Res Public Health 18(5):2686. https://doi.org/10.3390/ijerph18052686
Dotson S, Ciarocco S, Koh KA (2020) Disaster psychiatry and homelessness: creating a mental health COVID-19 response. Lancet Psychiatry 7(12):1006–1008. https://doi.org/10.1016/S2215-0366(20)30343-6
Favre L, Pantet O, Papadimitriou Olivgeris M (2021) Obesity and COVID-19: mechanisms involved in the collusion of two pandemics. Rev med suisse 17(731):558–563
Friedman J, Beletsky L, Schriger DL (2021) Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiat 78(5):562. https://doi.org/10.1001/jamapsychiatry.2020.4218
Gaume J, Schmutz E, Daeppen J-B, Zobel F (2021) Evolution of the illegal substances market and substance users’ social situation and health during the COVID-19 pandemic. Int J Environ Res Public Health 18(9):4960. https://doi.org/10.3390/ijerph18094960
Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC (2020) The impact of COVID-19 on syringe services programs in the United States. AIDS Behav 24(9):2466–2468. https://doi.org/10.1007/s10461-020-02886-2
Hammersley V, Donaghy E, Parker R, McNeilly H, Atherton H, Bikker A, Campbell J, McKinstry B (2019) Comparing the content and quality of video, telephone, and face-to-face consultations: a non-randomised, quasi-experimental, exploratory study in UK primary care. Br J Gen Pract 69(686):e595–e604. https://doi.org/10.3399/bjgp19X704573
Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P (2020) Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: provider perspectives. J Subst Abus Treat 124:108223. https://doi.org/10.1016/j.jsat.2020.108223
Hser Y-I, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, Mooney LJ, Curtis ME, Marsch LA, McLeman B, Hichborn E, Lester LS, Baldwin L-M, Liu Y, Jacobs P, Saxon AJ (2021) Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a national drug abuse treatment clinical trials network trial. Addict Sci Clin Pract 16(1):24. https://doi.org/10.1186/s13722-021-00233-x
Hsu M, Ahern DK, Suzuki J (2020) Digital phenotyping to enhance substance use treatment during the COVID-19 pandemic. JMIR Ment Health 7(10). https://doi.org/10.2196/21814
Jakubowski A, Fox A (2020) Defining low-threshold buprenorphine treatment. J Addict Med 14(2):95–98. https://doi.org/10.1097/ADM.0000000000000555
Jo Y, Bartholomew TS, Doblecki-Lewis S, Rodriguez A, Forrest DW, Tomita-Barber J, Oves J, Tookes HE (2020) Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLos One 15(4):e0231424. https://doi.org/10.1371/journal.pone.0231424
Kale N (2019) Urine drug tests: ordering and interpreting results. Am Fam Physician 99(1):33–39. https://www.aafp.org/afp/2019/0101/p33.html
Kleinman MB, Felton JW, Johnson A, Magidson JF (2021) “I have to be around people that are doing what I’m doing”: the importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities. J Subst Abus Treat 122:108182. https://doi.org/10.1016/j.jsat.2020.108182
Lekas H-M, Siegel K, Leider J (2011) Felt and enacted stigma among HIV/HCV-coinfected adults: the impact of stigma layering. Qual Health Res 21(9):1205–1219. https://doi.org/10.1177/1049732311405684
Levy J (2014) The harms of drug use: criminalisation, misinformation and stigma. International Network of People That Use Drugs (INPUD). https://www.inpud.net/The_Harms_of_Drug_Use_JayLevy2014_INPUD_YouthRISE.pdf
Lintzeris N, Hayes V, Arunogiri S (2020) Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID-19: a national response. Available at: https://www.racp.edu.au//docs/default‐source/news‐and‐events/covid‐19/interim‐guidance‐delivery‐of‐medication‐assisted‐treatment‐of‐opiod‐dependence‐covid‐19.pdf?sfvrsn=e36eeb1a_4
Lockard RA, Priest KC, Brown PCM, Graveson A, Englander H (2020) Addressing a rapidly changing service landscape during the COVID-19 pandemic: creation of the Oregon substance use disorder resource collaborative. J Subst Abus Treat 124:108244. https://doi.org/10.1016/j.jsat.2020.108244
Lopez AM, Lam K, Thota R (2021) Barriers and facilitators to telemedicine: can you hear me now? Am Soc Clin Oncol Educ Book 41:25–36. https://doi.org/10.1200/EDBK_320827
Mahase E (2021) Delta variant: what is happening with transmission, hospital admissions, and restrictions? BMJ n1513. https://doi.org/10.1136/bmj.n1513
Mark TL, Gibbons B, Barnosky A, Padwa H, Joshi V (2021) Changes in admissions to specialty addiction treatment facilities in California during the COVID-19 pandemic. JAMA Netw Open 4(7):e2117029. https://doi.org/10.1001/jamanetworkopen.2021.17029
McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ (2021) Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines 6(1):1–14. https://doi.org/10.1038/s41541-021-00336-1
McDonnell A, MacNeill C, Chapman B, Gilbertson N, Reinhardt M, Carreiro S (2020) Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response. J Subst Abus Treat 124:108226. https://doi.org/10.1016/j.jsat.2020.108226
Molfenter T, Roget N, Chaple M, Behlman S, Cody O, Hartzler B, Johnson E, Nichols M, Stilen P, Becker S (2021) Use of telehealth in substance use disorder services during and after COVID-19: online survey study. JMIR Ment Health 8(2):e25835. https://doi.org/10.2196/25835
Mukherjee TI, El-Bassel N (2020) The perfect storm: COVID-19, mass incarceration and the opioid epidemic. Int J Drug Policy 83:102819. https://doi.org/10.1016/j.drugpo.2020.102819
Murphy SM, Yoder J, Pathak J, Avery J (2021) Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic. J Subst Abus Treat 121:108177. https://doi.org/10.1016/j.jsat.2020.108177
National Institute on Drug Abuse [NIDA] (2020) Common comorbidities with substance use disorders research report. NIDA. https://www.drugabuse.gov/download/1155/common-comorbidities-substance-use-disorders-research-report.pdf?v=5d6a5983e0e9353d46d01767fb20354b
Never Use Alone (2020) FAQ – never use alone. https://neverusealone.com/faq/
Nunes EV, Levin FR, Reilly MP, El-Bassel N (2021) Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade? J Subst Abus Treat 122:108196. https://doi.org/10.1016/j.jsat.2020.108196
Oesterle TS, Kolla B, Risma CJ, Breitinger SA, Rakocevic DB, Loukianova LL, Hall-Flavin DK, Gentry MT, Rummans TA, Chauhan M, Gold MS (2020) Substance use disorders and telehealth in the COVID-19 pandemic era. Mayo Clin Proc 95(12):2709–2718. https://doi.org/10.1016/j.mayocp.2020.10.011
Office for National Statistics [ONS] (2021) Deaths related to drug poisoning in England and Wales: 2020 registrations. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2019registrations
Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guydish JR (2021) Impacts of COVID-19 on residential treatment programs for substance use disorder. J Subst Abus Treat 123:108255. https://doi.org/10.1016/j.jsat.2020.108255
Pines JM, Zocchi MS, Black BS, Carlson JN, Celedon P, Moghtaderi A, Venkat A (2021) How emergency department visits for substance use disorders have evolved during the early Covid-19 pandemic. J Subst Abus Treat 129:108391. https://doi.org/10.1016/j.jsat.2021.108391
Pytell JD, Rastegar DA (2021) Down the drain: reconsidering routine urine drug testing during the COVID-19 pandemic. J Subst Abus Treat 120:108155. https://doi.org/10.1016/j.jsat.2020.108155
Qeadan F, Tingey B, Bern R, Porucznik CA, English K, Saeed AI, Madden EF (2021) Opioid use disorder and health service utilization among COVID-19 patients in the us: a nationwide cohort from the Cerner Real-World Data. EClinicalMedicine 37:100938. https://doi.org/10.1016/j.eclinm.2021.100938
Richard L, Booth R, Rayner J, Clemens KK, Forchuk C, Shariff SZ (2021) Testing, infection and complication rates of COVID-19 among people with a recent history of homelessness in Ontario, Canada: a retrospective cohort study. Can Med Assoc Open Access J 9(1):E1–E9. https://doi.org/10.9778/cmajo.20200287
Roederer T, Mollo B, Vincent C, Nikolay B, Llosa AE, Nesbitt R, Vanhomwegen J, Rose T, Goyard S, Anna F, Torre C, Fourrey E, Simons E, Hennequin W, Mills C, Luquero FJ (2021) Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study. Lancet Public Health 6(4):e202–e209. https://doi.org/10.1016/S2468-2667(21)00001-3
Rosca P, Shapira B, Neumark Y (2020) Isolating the isolated: implications of COVID-19 quarantine measures on in-patient detoxification treatment for substance use disorders. Int J Drug Policy 83:102830. https://doi.org/10.1016/j.drugpo.2020.102830
Roxburgh A, Jauncey M, Day C, Bartlett M, Cogger S, Dietze P, Nielsen S, Latimer J, Clark N (2021) Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. Harm Reduct J 18(1):20. https://doi.org/10.1186/s12954-021-00471-x
Sárosi P (2020, March 16th) Harm reduction responses to COVID-19 in Europe: regularly updated infopage. Drugreporter. https://drogriporter.hu/en/how-harm-reducers-cope-with-the-corona-pandemic-in-europe/
Sarvey D, Welsh JW (2021) Adolescent substance use: challenges and opportunities related to COVID-19. J Subst Abus Treat 122:108212. https://doi.org/10.1016/j.jsat.2020.108212
Schlosser A, Harris S (2020) Care during COVID-19: drug use, harm reduction, and intimacy during a global pandemic. Int J Drug Policy 83:102896. https://doi.org/10.1016/j.drugpo.2020.102896
Scottish Families Affected by Alcohol and Drugs (2020, May 25th) Our’ click & deliver’ Take-home Naloxone service is now live. SFAD. https://www.sfad.org.uk/our-click-deliver-take-home-naloxone-service-is-now-live
Shachar C, Engel J, Elwyn G (2020) Implications for telehealth in a postpandemic future: regulatory and privacy issues. JAMA 323(23):2375–2376. https://doi.org/10.1001/jama.2020.7943
Stanojlović M, Davidson L (2021) Targeting the barriers in the substance use disorder continuum of care with peer recovery support. Subst Abuse Res Treat 15:1178221820976988. https://doi.org/10.1177/1178221820976988
Substance Abuse and Mental Health Services Administration [SAMHSA] (2021, January 27th) Become a Buprenorphine Waivered Practitioner. https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner
Taylor JL, Ruiz-Mercado G, Sperring H, Bazzi AR (2021) A collision of crises: addressing an HIV outbreak among people who inject drugs in the midst of COVID-19. J Subst Abus Treat 124:108280. https://doi.org/10.1016/j.jsat.2021.108280
Trujols J, Larrabeiti A, Sànchez O, Madrid M, De Andrés S, Duran-Sindreu S (2020) Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? J Subst Abus Treat 119:108154. https://doi.org/10.1016/j.jsat.2020.108154
Tyndall M (2020) Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy 83:102880. https://doi.org/10.1016/j.drugpo.2020.102880
Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA (2020) Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abus Treat 118:108124. https://doi.org/10.1016/j.jsat.2020.108124
Volkow ND (2020) Collision of the COVID-19 and addiction epidemics. Ann Intern Med M20:1212. https://doi.org/10.7326/M20-1212
Wainwright JJ, Mikre M, Whitley P, Dawson E, Huskey A, Lukowiak A, Giroir BP (2020) Analysis of drug test results before and after the US declaration of a National Emergency Concerning the COVID-19 outbreak. JAMA 324(16):1674–1677. https://doi.org/10.1001/jama.2020.17694
Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL (2021) Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abus Treat 124:108272. https://doi.org/10.1016/j.jsat.2020.108272
Wang QQ, Kaelber DC, Xu R, Volkow ND (2021) COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry 26(1):30–39. https://doi.org/10.1038/s41380-020-00880-7
Whitfield M, Reed H, Webster J, Hope V (2020) The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. Int J Drug Policy 83:102851. https://doi.org/10.1016/j.drugpo.2020.102851
Wilkinson R, Hines L, Holland A, Mandal S, Phipps E (2020) Rapid evidence review of harm reduction interventions and messaging for people who inject drugs during pandemic events: implications for the ongoing COVID-19 response. Harm Reduct J 17(1):95. https://doi.org/10.1186/s12954-020-00445-5
Woolley K, Smith R, Arumugam S (2020) Personal protective equipment (PPE) guidelines, adaptations and lessons during the COVID-19 pandemic. Ethics Med Public Health 14:100546. https://doi.org/10.1016/j.jemep.2020.100546
World Health Organization [WHO] (2022) WHO Coronavirus (COVID-19) dashboard. https://covid19.who.int/
Yazdi K, Fuchs-Leitner I, Rosenleitner J, Gerstgrasser NW (2020) Impact of the COVID-19 pandemic on patients with alcohol use disorder and associated risk factors for relapse. Front Psych 11. https://doi.org/10.3389/fpsyt.2020.620612
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Shapira, B., Neumark, Y. (2022). Substance Use Disorder Treatment in the Age of COVID-19: Challenges, Responses, and Lessons for the Future. In: Patel, V.B., Preedy, V.R. (eds) Handbook of Substance Misuse and Addictions. Springer, Cham. https://doi.org/10.1007/978-3-030-67928-6_17-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-67928-6_17-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-67928-6
Online ISBN: 978-3-030-67928-6
eBook Packages: Springer Reference MedicineReference Module Medicine